Patient Safety Movement Foundation (PSMF) – a global non-profit dedicated to unifying those involved in the healthcare ecosystem, identifying challenges that are causing patient deaths, and creating actionable solutions to mitigate them – is pleased to announce the appointment of its new chairman of the board of directors – Michael A.E. Ramsay, MD, FRCA. It also reaffirms its commitment to patient health and safety with updates to its mission, vision and values; and reestablishes its goal of achieving ZERO preventable patient deaths by 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200310005733/en/ As one of PSMF’s longest-standing board members, serving since 2013, Dr. Ramsay has been an advocate for patient safety in the anesthesia world since the 1980’s and embodies the values and principles......

Khartoum, March 11 (SUNA) – The Federal Minister of Health Dr. Akram Ali Al-Tom has said that his ministry’s budget for the fiscal year 2020 has tripled compared to the previous year 2019.

The minister indicated that the budget of the Ministry of Health increased from 16 billion pounds in 2019 to 51 billion pounds in 2020, more than 310%, adding that this increase aims to reduce the cost of treatment, expressing his concern on the inflation"...

Regulatory News:

Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The company exceeded its raised guidance for full-year 2019 on both net sales and EBITDA.

FINANCIAL PERFORMANCE: STRONG SALES AND PROFIT GROWTH CONTINUES

• Net"...

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO™ (ixazomib) to lenalidomide and dexamethasone in newly diagnosed transplant ineligible multiple myeloma patients. The addition of ixazomib to lenalidomide and dexamethasone resulted in an improvement in median progression-free survival (PFS) of 13.5 months (35.3 months versus 21.8 months; hazard ratio [HR] 0.83; p=0.073); however, it did not meet the threshold for statistical significance. The safety profile associated with NINLARO from the TOURMALINE-MM2 trial was generally consistent with the existing prescribing information. Results from the TOURMALINE-MM2 study will be submitted to an upcoming medical congress. “There is a need for treatment options in transplant ineligible patients. We remain......

Global Health & Pharma (GHP), a global information sharing platform & a multi-disciplinary members community announced winners of the 2019 Technology Awards this month and recognised Sinterex as Best 3D-Printed Healthcare Products Manufacturer – Middle East.

In its announcement, GHP said, “Technology is a great force for change across numerous industries, sectors and fields. In the global healthcare industry, it has become a"...

Khartoum, Mar. 8 (SUNA) The Director General, in charge of the National Public Health Laboratory (Stack) Professor Abu Bakr Ibrahim Ahmed affirmed that the laboratory is equipped with the latest molecular biology devices for diagnosing viruses, including the Corona virus, pointing out that Stack is identical in terms of devices and testing materials like those in Robert Koch Institute in Berlin, Germany.

in an interview with SUNA, to be published"...

Takeda Pharmaceutical Company Limited (TOKYO:4502/NYSE:TAK) (“Takeda”) today will share with members of the United States Congress that it is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with COVID-19, while also studying whether Takeda’s currently marketed and pipeline products may be effective treatments for infected patients. SARS-CoV-2 is the virus that causes COVID-19. Hyperimmune globulins are plasma derived-therapies that have previously been shown to be effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19. As a leader in plasma-derived therapies with more than 75 years of experience in the development of plasma-derived products, Takeda has the expertise to research, develop, and manufacture a potential anti-SARS-CoV-2 polyclonal......

In observance of International Women’s Day, Fakih IVF Fertility Center is rolling out a special campaign supporting all women and their choices. The campaign is running throughout March, across the center’s branches located in Abu Dhabi, Dubai and Al Ain.

With majority of women considering delaying pregnancy or choosing to embrace motherhood later in their lives, the various methods of fertility preservation available today give them"...

Authorities of the Abyei municipality have banned the smoking of water-pipe tobacco in public places in Abyei town.

The smoking of water-pipe tobacco, popularly known as shisha, has become increasingly popular with young people in the disputed region of Abyei.

Speaking to Abyei Today programme earlier this week, Dut Piok Amour, the Executive Director of Abyei town municipality"...

– If Approved by the European Medicines Agency, ALUNBRIG Would Become an Important First-Line Treatment Option for ALK+ NSCLC Patients –

– Positive Opinion is Based on Data from Phase 3 ALTA-1L Trial, in which ALUNBRIG Demonstrated Superiority in both Overall and Intracranial Efficacy Compared to Crizotinib –

Takeda Pharmaceutical Company Limited"...